UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2021

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street Park Rehovot P.O.B 2100

Rehovot 7612002 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Attached hereto and incorporated by reference herein are the following exhibits:

99.1Evogene Investor Presentation.

99.2AgPlenus Investor Presentation.
99.3Biomica Investor Presentation.
99.4Canonic Investor Presentation.
99.5Lavie Bio Investor Presentation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: April 19, 2021

By: /s/ Dorit Kreiner Dorit Kreiner Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION 99.1 Evogene Investor Presentation. 99.2 AgPlenus Investor Presentation.99.3 Biomica Investor Presentation. 99.4Canonic Investor Presentation.

99.5Lavie Bio Investor Presentation.

DECODING BIOLOGY

INVESTOR PRESENTATION

Ofer Haviv, President & CEO April 2021

Forward Looking Statement

This presentation contains "forward-looking to future events, and Evogene Ltd (the "Company"), may from time to time nake other statements, regarding our outlook or expectations for operating results and/or other matters regarding or affecting us that are considered "forward-boking statements" as defined in the U.S. Private Securities in 1995 (the "S.R.A") and other securities laws. Such forward-boking statements may be identified by the use of such words as "believe", "should", "planned", "intend" and "potential" or words of similar meaning. We are using forward-boking statements in this presentation we discuss our value divers and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain isks and uncertaintes which are difficult to predict and are not guarance. Therefore, actual future results, performance or achievements, and rends in the future nay differ materially from what is expessed or impled by such forward-hoving statements due to a variety of factors, many of which are beyond our control, including, without linitation, those detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Comnission, including "hish Factors".

Except as required by applicable securities any obligation or commitment to update any information on to publicy release the results of any revisions that may be made to reflect future events or changes in expectations, estmates, propections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or offer to sell, or any solicitation of any invitation or offer to purches of Evogen or the Company, nor shall the information or any part of it or the fact of its distribution form the bass of or be relied on in contract, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the used for reference purposes only. Such use should not be construent of our products or services.

evogene

Agenda

* Introduction

Fields of activity

Main subsidiaries

Summary

Annex I - Addressing the discovery and development challenges of life science-based product

Annex II - Financial Fundamentals

evøgene

OUR VISION

Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.

DECODING BIOLOGY

evøgene

Life-science product discovery & development challenges

Low probability of success with high cost and long time-to-market

*Center for Drug Evaluation and Research

The opportunity

Utilize comprehensive and integrated computational biology to substantially increase the probability of success, while reducing the time and cost of life-science product discovery & development.

When biology meets disruptive technologies; introducing-

Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), to successfully discover & guide the development of novel life-science based products.

Developed over two decades at an investment of tens of millions of dollars and validated through collaborations with industrial leaders & internal results

Tailor-made Engines for product discovery & development

The CPB platform enhances product discovery and development through dedicated Engines for products based on three core components:

· Microbes
· Small molecules
· Genetic elements

evogene

Tailor-made Engines for product development

+ Discovery

Computational selection of the most promising candidates to initiate the product development process.

+ Development

Computational driven solution addressing optimization development challenges for the selected candidates, without impairing their ability to address other product attributes, supporting the way to successful commercialization.

evogene

Product development through collaborations

Joint development with leading companies for defined products utilizing Evogene's unique solution. Later-stage development and commercialization of the product will likely be done by the partner.

Potential revenue for Evogene

· Licensing and research payments
· Milestone payments
· Revenue sharing

Main Business Model Until 2014:

GMO seed traits for yield

and abiotic stress for wheat

MONSANTO &

· GMO seed traits for yield and abiotic stress and abiotic stress for corn and soybean
- GMO seed traits for ASR resistance for soybean

for corn

· GMO seed traits for yield · · GMO seed traits for nematode resistance
· GMO (2013) and genome editing (2019) seed traits for fusarium resistance

evogene

Product development through subsidiaries

Establish independent entities focusing on a defined commercial field with an exclusive license to use Evogene's unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategic collaborations.

Potential revenue for Evogene

· Licensing and research payments
· Consolidated revenues
· Dividends (subject to profits generated by subsidiary)

Main Business Model from 2015:

casterra

Ag-solutions for castor

Agenda

* Introduction

Fields of activity

Main subsidiaries

Summary

Annex I - Addressing the discovery and development challenges of life science-based product

Annex II - Financial Fundamentals

evøgene

Potential fields of activity


	ം Micro 33 Boost A	MICROBES
CPB	Chem PassAl	SMALL MOLECULES
	Gene ARator Al	GENETIC ELEMENTS

evøgene

Current life-science based products under development

AN MINAL WALANATING
			HUMAN HEALTH	AGRICULTURE	OTHER INDUSTRIES
	So Micro BoostA	MICROBES	Microbiome based Therapeutics	Ag-Biologicals
CPB	Chem PassA	SMALL MOLECULES	Drugs based on small molecules	Ag-Chemicals
	Gene Rator Al	ELEMENTS GENETIC	Medical Cannabis	Seed Traits	Ag-solutions for castor oil production

evøgene

Development & commercialization through subsidiaries and collaborations

* non-exclusive license

evogene

Evogene Group - More to Come

* under evaluation

+ New activity

We are now evaluating the initiation of discovery and development of new lifescience based products in various new fields of activity.

evogene

*Evogene holdings

Agenda

* Introduction Fields of activity Main subsidiaries

Summary

Annex I - Addressing the discovery and development challenges of life science-based product

Annex II - Financial Fundamentals

Mission:

Discovery and development of novel therapies for microbiome-related human disorders using computational biology.

Product Pipeline:

ሩን

Immuno-oncology program:

· Combination therapy for cancer with checkpoint inhibitors
· Pre-clinical stage
· Addressable market size expected by 2026* \$243B

GI related disorders:

· Inflammatory Bowel Disorder (IBD) pre-clinical stage
· Irritable Bowel Syndrome (IBS) discovery stage
· Addressable market size expected by 2026: Inflammatory Bowel Disorder \$22.4B, Irritable Bowel Syndrome** \$3.3B

MDRO:

to-fuel-market-growth-observes-transparency-market-research-676949593.html

· Multi Drug Resistant Organisms (antimicrobial resistance)
· Clostridium Difficile Infection (CDI) discovery stage
· Methicillin-resistant Staphylococcus aureus (MRSA)- discovery stage
· Addressable market size expected by 2026: CDI*** \$1.7B, MRSA**** \$3.9B

*https://www.globenewswire.com/news-release/2019/07/1289118/0/er/Cancer-Immunotherapy-Narket-To-Reach-USD-242-Reports-Ad-Data.html ** https://www.bloomberg.com/press-releases/2019-07-23/bs-treatment-market-size-worth-3-3-billion-by-2025-cagr-10-1-grand-view-research-inc-***www.globaldata.com/global-clostridium-difficile-infections-market-approach-1-7-billion-2026/

*** www.pmersvire.com/news-released/global-nethiolifi-resident-statly/vices-arees-se-strum-by-2025-upsurge-in-the-consumption-d-atibicits-acoss-the-stitle-

Expected main near-term value drivers:

2021

· IBD extend pre-clinical study
· Immuno-oncology initiate proof of concept, first in human study

2022

· IBD initiate first GMP production of drug candidates for IBD
· Immuno-oncology readout from proof of concept, first in human study

Example Results:

Immuno-Oncology program - BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo

Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone

evogene

Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program

Biomica's, a subsidiary of Evogene Ltd., live biotherapeutic drug candidate BMC128 administered in combination with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity. Proof-of-concept first-in-man studies expected next year

Rehovot, Israel - September 8, 2020 - Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced positive pre-clinical in-vivo results in its immuno-oncology program for a follow-on combination of bacterial strains. In these studies, Biomica tested BMC128, which consists of four live bacterial strains derived from Biomica's drug candidates BMC121 and BMC127. Treatment with BMC128, both prior to and in combination with ICI, significantly improved anti-tumor activity in mice.

Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma

Biomica's live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year

Rehovot, Israel - April 13, 2021 - Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced additional positive pre-clinical results in its immuno-oncology program demonstrating efficacy of its live biotherapeutic product (LBP) consortium BMC128, this time in melanoma. In these studies, Biomica tested BMC128, which consists of four live bacterial strains, in a mouse model of melanoma.

CANONIC | Medical Cannabis

Mission:

Commercialize precise & stable medical cannabis products for better therapeutic effects using computational biology.

Gene Rator

Product Pipeline:

MetaYield Products:

· Stable enhancement of total plant compounds:
- · Increased compounds per plant
- · Increased compounds per area
· Total Cannabis market size expected by 2024 \$42.7B*

Precise Products:

Stable enhancement of specific active compounds for pain and inflammation:
- · Medical indication focus
- · Compound profile focus
· Medical · Cannabis market size expected by 2024 \$25.6B*

Expected main near-term value drivers:

2002

· MetaYield reach 1st commercial variety; sign production and distribution agreements in anticipation for commercialization in 2022
· Precise identify specific lines that exhibit distinct effect in model systems for reducing pain or inflammation

2022

· MetaYield commercial launch and initial sales of first product in Israel
· Precise reach 1st commercial variety for reducing pain or inflammation as preparation for commercial launch in 2023

*Source: Arcview Market research/BDS Analytics 2020

evøgene

CANONIC | Medical Cannabis

Example Results:

MetaYield products under development - increased compounds per area, addressing the T20/C4 (THC 16%-24% and CBD 0%-7%) market segment, which currently consists of 70% of the Israeli medical cannabis market

Medical Cannabis aiming at high THC, high yield, big inflorescence and dense trichomes Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products

Collaboration to combine the cannabis expertise of both parties, including extensive clinical and related data of Cannbit and leading computational predictive biology capabilities and genomic data of Canonic

Tel-Aviv and Rehovot, Israel - February 24th, 2021 - Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. (TASE: TKUN), a leading medical cannabis company, and Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), focused on the development of medical cannabis products, today announced that they have entered into a collaboration agreement for the development of novel medical cannabis products.

Canonic of Evogene Group and Tikun Olam (Israel)-Cannbit, sign production and distribution agreements for Canonic products in Israel

Rehovot and Tel-Aviv, Israel - March 25th, 2021 - Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), focused on the development of medical cannabis products and Tikun Olam-Cannbit Pharmaceuticals Ltd. (TASE: TKUN), a leading medical cannabis company, today announced that they have entered into agreements for the production and distribution in Israel of Canonic's medical cannabis products. Canonic's first product is expected to be launched in Israel next year.

DECODING BIOLOGY * 22

evogene

Mission:

Design of next-generation effective, sustainable and safer crop protection products by leveraging computational biology and chemistry.

Product Pipeline:

Expected main near-term value drivers:

Herbicides:

Novel MoA (Mode-of-Action) selective/non-selective herbicides
· Relevant target crops Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar Beet, Other TBD
· Addressable market size expected by 2022 *: \$34B
· Lead stage

Insecticides:

· Novel SoA (Site-of-Action)
· Addressable market size expected by 2022*: \$19B
· Hit-to-Lead stage

2021

· New MoA Herbicide reach a herbicide tolerance trait POC for a `Lead' herbicide under development
· New MoA Herbicide/SoA Insecticide sign a licensing agreement for a leading candidate

2022

· New MoA Herbicide sign a strategic agreement for the development of an `Optimized Lead' compound
· New MoA Herbicide reach an 'Optimized Lead' phase in the herbicide program

*https://www.prnewswire.com/news-releases/global-3410-billion-herbicide-market-2022--research-and-markets-300458389.html

Example Results:

Leading novel MoA herbicide candidate - displaying efficacy in eradicating multiple important weed species in field tests

Field test of APH1 against a panel of grass and broadleaf weeds - untreated control vs APH1

evogene

AgPlenus Announces Reaching a 'Lead' Stage in its Novel Mode-of-Action Herbicide Program

This significant development milestone was achieved following positive results for product candidate APH1 in field tests with commercial level application rates on a broad panel of weeds

Rehovot, Israel - December 15, 2020 - AgPlenus Ltd., an innovative company designing effective, sustainable crop protection products by leveraging computational biology and chemistry, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), announced today that it has reached the 'Lead' stage in its novel Mode-of-Action (MoA) herbicide program. The achievement of this milestone follows the conclusion of field tests that demonstrated that product candidate APH1, at commercial dose rates, effectively controlled a broad panel of weeds, including weeds that are known to have resistance to existing herbicides. These results were confirmed in independent field tests conducted by SynTech Research, an agricultural R&D contract research organization located in California.

Mission:

Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products using computational biology.

Product Pipeline:

Bio-stimulants (live microbials for yield improvement):

development stage 2
· Corn seed treatment pre-development stage

· Spring wheat - seed treatment/soil application -

· Addressable market size * : corn - 120M acres, spring wheat - 25M acres

Bio-pesticides (live microbials for pest protection):

· Mildew, fruit rot for fruit and vegetables (initial focus on grapes) - foliar application - development stage 1
Seedling disease for corn, soy seed treatment for disease protection - pre-development stage
Bio-insecticides initial focus corn (seed treatment), soy (foliar) - pre-development stage
· Addressable market size *: mildew, fruit rot \$550M, seedling diseases - \$500M, bio-insecticides - \$1.5B.

*Company estimation

evogene

Expected main near-term value drivers:

2021

· Fruit rot bio-fungicide product advancement of LAV311 or 312 development towards regulation
· Bio-stimulant conduct pre-commercial trials for LAV211 in spring wheat
Bio-stimulant initial product sales of LAV211 for spring wheat
· Fruit rot bio-fungicide file for regulatory approval for leading product candidate LAV311 or LAV312

Example of treatment with LAV312 against Botrytis Cinerea in vines - untreated control vs treated vines

Lavie Bio Announces Positive Results for LAV311 and LAV312 in its Bio-Fungicide Program

Positive results were achieved in a series of vineyard trials for bunch rot diseases conducted in Europe and the United States

Rehovot, Israel - October 29, 2020 - Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today positive trial results for two of its leading bio-fungicide product candidates. The successful results for LAV311 and LAV312, targeting bunch rot diseases, mark the advancement of these candidates to "Development Stage 2" [1] These vineyard trials, conducted in target locations in Europe and the U.S., resulted in significantly better efficacy and consistency than existing comparable commercial biological benchmarks, and competitive to commercial chemical benchmarks, both tested as part of these trials. The positive results will support Lavie Bio's current plan to launch its first biofungicide product for controlling bunch rots for use in fruit and vegetables in 2024.

Lavie Bio's wheat field in the USA during harvest

Lavie Bio Provides Product Pipeline Update for 2020

LAV211 bio-stimulant advancing towards anticipated 2022 commercial launch in spring wheat; Product advancement achieved in multiple programs

Rehovot, Israel - December 29, 2020 - Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), has announced an update on certain advancements achieved in its pipeline in 2020, including phase advancement of bio-stimulant LAV211, towards an anticipated commercial launch in 2022.

evogene

Subsidiaries - expected main near-term value drivers

Agenda

* Introduction - Fields of activity Main subsidiaries

Summary

Annex I - Addressing the discovery and development challenges of life science-based product

Annex II - Financial Fundamentals

Summary

Our vision - Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.

CPB platform - a unique technology platform stemming from the incorporation of deep scientific understandings of biology together with big-data and artificial intelligence technologies

The CPB's three unique engines target to improve the development of products based on the following core components:

1. MicroBoost AI for products based on microbes
1. ChemPass AI for products based on small molecules
1. GeneRator AI for products based on genetic elements

Dual based business model - utilizing Evogene's solutions for:

1. Product development & commercialization through collaborations
1. Product development & commercialization through subsidiaries

Four main market-oriented subsidiaries, each with a clear milestone roadmap:

1. Biomica human-microbiome based therapeutics
1. Canonic medical cannabis
1. AgPlenus ag-chemicals
1. Lavie Bio ag-biologicals

Significant catalysts expected in the next 12 months towards 2022 product commercialization & strategic collaborations

evogene

THANK YOU!

Annex I: Addressing the discovery and development challenges of life science-based product

evogene

evøgene

The challenge in creating life-science based products

Common practice

Discovery - selection of product candidates mainly addressing efficacy

Candidate Selection

Efficacy Safety Selectivity

Shelf-life

Other

evøgene

DECODING BIOLOGY * 33

Product

Launch

The challenge in creating life-science based products

Common practice

Discovery - selection of product candidates mainly addressing efficacy

Development - inefficient optimization & difficulty in addressing a single challenge without impairing others

X Low probability of success

X Long time to market

X High development costs

Product Candidate Definition Selection

Efficacy

Safety

Selectivity

Shelf-life

Launch

Product

Other

evogene

evøgene

Evogene's AI-based solution: Development

A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes.

evogene

Evogene's AI engines provide tailor-made solutions

+ Discovery

Computational prediction of candidates, to serve as the product's core-component, addressing multiple key product attributes.

+ Development

Computational driven solution for guiding and assessing the optimization process of the selected core component, without impairing other key product attributes.

evogene

Annex II: Financial Fundamentals

evøgene

Key Financials: Balance Sheet

Thousands of US \$	31.12.2020	31.12.2019
Current Assets	51,823	49,027
Long-Term Assets	20,092	22,337
Total Assets	71,915	71,364
Current Liabilities	9,676	5,746
Long-Term Liabilities	5,357	5,401
Equity attributable to equity holders of the Company	46,045	50,144
Non-controlling interest	10,837	10,073
Total Liabilities & Shareholders Equity	71,915	71,364

Key Points:

· Consolidated cash position: ~\$48.2 million as of 31.12.2020, ~\$13 million appropriated to Lavie Bio
· No bank debt
· Estimated net cash usage for 2021, excluding Lavie Bio: \$20-\$22 million
· Listed on TASE (2007) and NASDAQ (2016)

evøgene

Exhibit 99.2

Forward-Looking Statements

This presentation contains forvard-loking to fulle events and Aple "Company") and its parent, Frogene Ltd. ("Livgene"), may from time make other statements, regarding our outlok or expections for operating results and or other matters regarding or attar are considered "boward-looking statements" as defined in the U.S. Private Securities Litgation Reform Act of 1995 (the "PSLR") and other securities statements may be identified by the use of such words as "believe", "anticipate", "should", "planed", "intend" or words of similar meaning. We are using forward-looking statements in this presention in this presention inter we discuss our value divers, commercialization efforment and launches, estimated make sizes and milestones, as well as the capabilies of Evogene's and our technology.

Such statements are based on current, projections and assumpions, describe opinons about future events, involve certain risk and uncertainles which are officulto predict and are not quarantees of future results, performance or achievents, and trends in the future may differ materially from what is expersed or implied by such forward-looling statements of thich are beyond our control, including, without limitation, those destilli in Jogen's Annual Report on Form 20-F and in other information is and field be israel Securites Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities are comminent or update any information contained in this presentation or to publicy release the esults of any revisions to any statements that may be made to refect future events or changes in expectations, estimates, projections and assumptions.

The information contained here not constitue a prospectus or other offering document, nor of any invitation or offer of any solication of any inviation or offer to purchase or securities of Evogene of the Company, nor shall the information of any part of the fact of the relevon in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks incuded herein are the property of and are used for reference purposes only. Such use should not be construed on and our products on services.

-- agPlenus

Agenda

· Company introduction
· Business model
· Product pipeline
· Technology
Milestone roadmap

We design next-generation, effective, sustainable and safer crop protection products by leveraging predictive biology & chemistry

4 agPlenus - 4 -

Growing market for Crop Protection products with need for innovation

No new Mode-of-Action (MoAs) for 3 decades Major Ag companies have failed to meet the demand for innovation

SagPlenus - 5

Herbicide resistant weeds have flourished

· Overuse of existing Modes of Actions (MoAs) has generated selection pressure
- · 263 herbicide-resistant weed species have evolved*

· Substantial economic cost to farmers

· Increase costs and reduce yields
· United States:
- · Soybeans: \$35/acre additional costs **
- · \$2 billion / year increased costs and lost yields ***

Sources * Intl. Herbicide Resistant Weed Database ** AgriBusiness Global, Farm Progress *** Michigan Farm News ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AgPlenus' target-based technology addresses the challenges

Experienced board of directors

Chairman of the board
· Evogene, President & CEO
· Previously, Syngenta, President USA

Robert A. Woods

· Marrone Bio Innovations, Inc., Chairman

· Bioenterprise capital private equity

Eli Assraf

· Galam Ltd., Director
· Previously, Makhteshim Agan (Adama), CFO & COO
· Strauss Group, CFO

Eran Kosover

· Previously AgPlenus Ltd., CEO
· Evogene EVP & GM Crop Protection, Evogene VP of collaborations,
SagPlenus - 8 -

· Atera Networks

Innovative & experienced management team

Douglas A. Eisner CEO

Previous positions:

· AgroSpheres, Inc., CEO
· GrassRoots Biotechnology, Inc., Co-

Boaz Inbal VP R&D

Previous positions:

· Epix pharmaceuticals, Director
· Insilicore, CEO
· Promining therapeutics, CTO

Mirit Ram Director of Project Management

Previous positions:

· Evogene, PM
· FMC, PM
· HP

founder and COO

Agenda

· Company introduction
· Business model
· Product pipeline
· Technology
Milestone roadmap

Product development stages

agPlenus - 10

Business model - value creation through product development process

Crop protection industry

· Dominated by four Major ag-chemical companies

· 70%* of ag-chemical crop protection market
· Pace of innovation and new product introductions have slowed
Looking to smaller, ag-tech companies to develop new small-molecule candidates
- · AgPlenus is leading the integration of computational technology to discover small molecules
- · Focusing on developing products with new MoAs

* Canadian Council on Food Safety and Health

agPlenus

Business model & potential revenue stream

PagPlenus

Corteva collaboration

· Develop new MoA herbicides to target resistant weeds

· Entered March 2020
· AgPlenus will discover and optimize herbicide candidates
· Corteva will conduct testing and product development

agPlenus -

· License to Corteva

· Corteva has exclusive license to products of collaboration
· AgPlenus receives research fees, milestones and royalties upon commercialization

· Goal for 2021

· Advance development of collaboration compounds

Agenda

· Company introduction
· Business model
· Product pipeline
· Technology
Milestone roadmap

Products under development

Herbicides:

· Novel MoA (Mode-of-Action) herbicides
· Optimize existing herbicides to overcome resistance
· High value crops Corn, Soybean, Cereals, Rice, Cotton, Canola ...
· By 2022, addressable market expected: \$34B

Insecticides:

Novel SoA (Site-of-Action)
By 2022, addressable market expected : \$19B

Sources: Research and Markets, Markets and Markets

"agPlenus

AgPlenus product pipeline

APH 1 - New MoA herbicide reached Lead stage

· Broad-spectrum weed control at commercial dosage rates
· Effective against resistant weed strains including Palmer Amaranth

APH 1 - a new MoA non-selective herbicide candidate

	Product Efficacy	· APH 1 displays herbicidal activity on multiple important weed species, both grasses and broad-leaves
New MOA		· APH 1 active on a new MoA - providing a solution to the rising resistance problem
	Market Potential	· Relevant target crops - Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar beet · Leading relevant geographies
Safety		· APH 1 target/MoA does not exist in human - high safety potential · Molecule safety predicted using multiple computational tools
	Production	· Molecule and several analogs synthesized Ongoing efforts to reduce production costs
	Product	· Good solubility, APH 1 active in water-based formulations Application · APH 1 active both in pre- and post-emergence applications

New MoA Herbicide active at commercial concentrations

20 agPlenus - 20 -

APH 1 - Product efficacy

Broad activity, pre and post application

APH 1 is a new MoA non-selective herbicide candidate Key next milestones

Agenda

· Company introduction
· Business model
· Product pipeline
· Technology
Milestone roadmap

AgPlenus technology empowered by Evogene's ChemPass Al

Computational prediction of multiple product attributes

From target to an optimized lead

SagPlenus - 26 -

Experimental pipeline up to 'Lead' stage

27 agPlenus - 27 -

Agenda

· Company introduction
· Business model
· Product pipeline
· Technology
· Milestone roadmap

Expected main near-term value drivers

2021

· New MoA Herbicide reach a herbicide tolerance trait POC for a 'Lead' herbicide under development
· New MoA Herbicide/SoA Insecticide sign a licensing agreement for a leading candidate

2022

· New MoA Herbicide reach an 'Optimized Lead' phase in the herbicide program
· New MoA Herbicide sign a strategic agreement for the development of an 'Optimized Lead' compound

agPlenus -

We are AgPlenus

Creating effective, sustainable and safer crop protection products

-- "agPlenus - 30 -

Exhibit 99.3

Forward Looking Statement

This presentation contains "forward-looking to future events, and Bionica Ltd (the "Company") and its parent Evogene Ltd. ("Evogene"), may from time to time make other statements, repartions for uture financial or operating results and/or other matters regarding or affecting us that are considered "fonwardlooking statements" as defined in the U.S. Privation Reform Act of 1956 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "belie"," should"," planned", "stimated", "intend" or words of smillar meaning. We are using forwardlooking statements in this presentation when we divers, commercialization efforts and timing, product development and launches izes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain isks and uncertainties which are difficult to predict and and guarantees of future results, performance or achievenents, and trends in the future may differ materially from what s expessed or implied by such forwards do a variety of factors, many of which are beyond our control, including, without imitation, those described in greater otail in Evogene's Annual Report on Frincipation Evogene files and furnishes with the Irael Securites Authority and the U.S. Securites and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disation or commitment to update any information or to publicy release the results of any evisions to any be made to reflect future events or developments or changes in expections and assumptions.

The information contained herein does not constitute offering document, nor does it constitute or form part of any invitation or offer o sell, or any soliciation of any invitation or offer to purchase or securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of or be relied on in conection with, any action commitment or to the securities of Evogene or the Company.

The trademaks included herein and are of and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

BIOMICA ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

HIGHLIGHTS

Mission

Developing innovative microbiome-based therapeutics

Emerging biopharmaceutical company

Focus

Treatment of immune-mediated and infectious diseases:

· Immuno-Oncology
· Gastrointestinal (GI) related disorders
· Antimicrobial resistance (AMR)

Pipeline

Enabled by a unique computational predictive biology platform (combining 'Big-Data' & Artificial Intelligence technologies)

The Microbiome and its Functions

The human gastrointestinal tract comprises approximately 10ª microbes and amounts to a biomass of approximately 2kg!

Trillions of microbes living in & on our bodies, acting as a "Other Genome"

For every human gene there are 100 microbial genes

Microbes play a critical role in food digestion, protection from diseases and production of nutrients

Clinical evidence is accumulating for microbiome's role in a wide array of illnesses

Solving dysbiosis, a state of microbial imbalance in the body, is at the core of new therapeutic approaches

Market Landscape

Biomica's Mission and Focus

Discovery and development of novel therapies for microbiome-related human disorders using computational predictive biology

The Challenge

Microbiome space is Big-Data driven

Multi-OMICS big-data & clinical meta-data needed for addressing specific biological questions

How to cope with enormous amount of information?

The common practice: The biological (trial and error) approach

It has 2 disadvantages:

A needle in a haystack ...

Guessing the lottery numbers

BIOMICA -

The Competitive Edge

Our computational technologies enable data integration, analysis & prediction

CPB platform

Databases generated via data integration capabilities

Proprietary computational algorithms (Al) utilized to mine data

Developed over two decades at an investment of tens of millions of dollars and validated through collaborations with industrial leaders & internal results

CPB - Computational Predictive Biology

BIOMICA -

Biomica's Edge

Our computational platform is capable of unprecedented high-resolution microbiome analysis Pioneers in the field of functional microbiome analysis, leading innovative technology

Minimum Microbial Strains

Maximum Relevant Functions

Maximal Therapeutic Impact

Advantages of our approach Vs. others in the field:

· Fecal Microbiota Transplant (FMT): Collection of 10,000s entities, no QC
· Single-strain method: We bring higher efficiency due to multiple MoAs
· Other multi-strain rationally-designed LBPs: We optimize a consortium for better efficacy with less adverse effects (due to fewer & carefully selected entities)

BIOMICA

Biomica's Discovery Pipeline

	Program	Indication / Target	Approach
Immuno- oncology (with ICI*)	BMC121	Combination Therapy for NSCLC **	ું જિ
	BMC127	Combination Therapy for NSCLC	ுத்த
	BMC128	Combination Therapy for NSCLC
GI related disorders	BMC321	IBD	ு. இந்
	BMC322	IBD	15
	BMC426	IBS	திர
Antimicrobial resistance (AMR***)	BMC202	C. difficile toxin-B

In the AMR Program, Biomica has a collaboration with Nobel Prize Laureate Prof. Ada Yonath at Weizmann Institute of Science to develop a selective treatment for MRSA

Biotherapeutics Small-molecule

BIOMICA

* Immune Checkpoint Inhibitors, ** Non-smal-cell lung carcinoma (NSCLC), ***Previously this program was referred to as "Multi-drug resistant organisms"

Response to Immunotherapy is Modulated Through Specific Bacterial Functions

*Based on Biomica's computational analysis

Fecal Microbiota Transplantation (FMT) and re-Induction of anti-PD-1 Therapy in Refractory Patients - POC

Clinical studies are testing whether cancer immunotherapy drugs work better when patients receive a fecal transplant. JEFF MCINTOSH/THE CANADIAN PRESS/AP PHOTO

Fecal transplants could help patients on cancer immunotherapy drugs

By Jocelyn Kaiser | Apr. 5, 2019 , 1:45 PM

BIOMICA bttps://www.sciencemag.org/news/2019/04/fecal-transplants-could-help-patients-cance-im

" ... Now, another potential therapy is being tested in clinical studies: fecal transplants. Early results from two groups described at the annual meeting of the American Association for Cancer Research (AACR) here this week suggest some patients who initially did not benefit from immunotherapy drugs saw their tumors stop growing or even shrink after receiving a stool sample from patients for whom the drugs worked ... "

" ... One unresolved question is exactly which microbes help ramp up the desired immune activity ... "

Modulating gut microbiota to treat cancer

Science

REPORTS

Cite as: E. N. Baruch et al., Science 10.1126/science.abb5920 (2020).

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Erez N. Baruch124+, Ilan Youngster34, Guy Ben-Betzalel', Rona Ortenberg', Adi Lahat5, Katerina Adler", Daniela Dick-Necula", Stephen Raskin*4, Naamah Bloch", Daniil Rotin", Liat Anaff", Camila Aviv", Jenny Melnichenko', Yael Steinberg-Silman', Ronac Mamtani", Hagit Harati', Nethanel Asher', Ronnie Shapira-Frommer', Tal Brosh-Nissimov2, Yael Eshet+313, Shira Ben-Simon10, Oren Ziv0, Md Abdul Wadud Khan'4, Moran Amit5, Nadim J. Ajamib4, Iris Barshack+6, Jacob Schachteri4, Jennifer A. Wargo416, Omry Koren10, Gal Markel1,2,17**, Ben Bours14,18,19+

CLINICAL TRIALS

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients

Diwakar Davar *, Amiran K. Dzutsev2*, John A. McCulloch2, Richard R. Rodrigues23, Joe-Marc Chauvin', Robert M. Morrison', Richelle N. Deblasio', Carmine Menna', Quanquan Ding', Ornella Pagliano , Bochra Zidit, Shuowen Zhang +, Jonathan H. Badger2, Marie Vetizou2, Alicia M. Cole2, Miriam R. Fernandes2, Stephanie Prescott2, Raquel G. F. Costa2, Ascharya K. Balaji2, Andrey Morgun", Ivan Vujkovic-Cvijin3, Hong Wang", Amir A. Borhani', Marc B. Schwartz", Howard M. Dubner®, Scarlett J. Ernst+, Amy Rose', Yana G. Najjar2, Yasmine Belkaid', John M. Kirkwood , Giorgio Trinchieri +8. Hassane M. Zarour13 +8

Anti-programmed cell death protein 1 (PD-1) therapy provides long-term clinical benefits with advanced melanoma. The composition of the gut microbiota correlates with anti-PD-1 efficacy in preclinical models and cancer patients. To investigate whether resistance to anti-PD-1 can be overcome by changing the gut microbiota, this clinical trial evaluated the safety and efficacy of responder-derived fecal microbiota transplantation (FMT) together with anti-PD-1 in patients with PD-1-refractory melanoma. This combination was well tolerated, provided clinical benefit in 6 of 15 patients, and induced rapid and durable microbiota perturbation. Responders exhibited increased abundance of taxa that were previously shown to be associated with response to anti-PD-1, increased CD8° T cell activation, and decreased frequency of interleukin-8expressing myeloid cells. Responders had distinct proteomic signatures, and transkingdom network analyses confirmed that the gut microbiome regulated these changes. Collectively, our findings show that FMT and anti-PD-1 changed the gut microbiome and reprogrammed the turnor microenvironment to overcome resistance to anti-PD-1 in a subset of PD-1 advanced melanoma.

Davar et al., Science 371, 595-602 (2021) 5 February 2021

1 | Cancer Immunotherapy - Combination Therapy

I | Initial Focus on Lung Cancer (NSCLC)

· Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide
· Current solutions reach only an average of 17%-20% overall response rate

Biomica aims to improve clinical response of ICI through immunomodulating combination therapy

BMC121 & BMC127

Rationally designed consortia aimed to facilitate antitumor activity in combination with ICI

· Orally administered capsule, comprised of 4 bacterial strains each, detected through Biomica's proprietary computational functional genomic analysis platform
· Strains were selected based on specific functional capabilities and their immuno-stimulatory potential
· The combination of 4 different microbial strains in a consortium is aimed to achieve effective immune activation through several underlying and complementary mechanisms

ter Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018.

BMC121 & BMC127 potentiate the effect of anti-PD1 therapy in vivo Mean Tumor Volume and Time To Endpoint significantly improved

Optimizing our IO consortia: BMC128

BMC128 administered prior to and in combination with anti-PD1 significantly improved anti-tumor activity

Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program

Rehovot, Israel - September 8, 2020 - Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced positive pre-clinical in-vivo results in its immuno-oncology program for a follow-on combination of bacterial strains. In these studies, Biomica tested BMC128, which consists of four live bacterial strains derived from Biomica's drug candidates BMC127. Treatment with BMC128, both prior to and in combination with ICI, significantly improved anti-tumor activity in mice.

ORR (CR+PR): 23.5% vs 34.8% 48% increase in responders

The study indicates that pre-treatment with BMC128 conditions the immune system and primes it for an efficient anti-tumor response

BIOMICA

`BMC 128 - Consist of 4 live bacterial strains derived from BMC121 and BMC127

Sep 8th, 2020

BMC128 Demonstrating Efficacy of in Melanoma

BMC128 significantly enhanced anti-tumor activity, resulting in an increased response of melanoma tumors to anti-PD1 LOG mean

CISION

News

Contact

Business & Money Science & Tech Lifestyle & Health Policy & Public Interest

These results demonstrate the potential applicability of BMC128 and its relevance to treating multiple types of solid tumors

BIOMICA -

Apr 13th, 2021

People & Culture

First-in-human, proof of concept study expected to initiate later this year

· BMC128 consists of 4 live bacterial strains
· Results demonstrated a significant reduction of tumor volume, and increased animal survival compared to anti-PD1 therapy alone
· MOA is immune mediated increased tumor inflammation & infiltration of T lymphocytes and NK cells
· Potential applicability in the treatment various types of solid tumors

BIOMICA ---

Predictor of Patients' Response to ICI Utilizing AI and PRISM-generated high-res microbiome profiles

2 GI Related Disorders
C IBS & IBD IBS & IBD

Irritable Bowel Syndrome (IBS).

A common intestinal functional disorder, group of symptoms:

· Abdominal Pain
· Constipation or Diarrhea
· Bloating, Gas & Diarrhea

In collaboration with The University of North Carolina (UNC) at Chapel Hill

Inflammatory Bowel Disease (IBD) **

A group of inflammatory conditions of the colon and small intestine (Crohn's disease, Ulcerative colitis & Pouchitis)

Approximate number of patients: 43M

Both clearly related to the microbiome

Biomica pushes the barriers posed by existing therapies by addressing the underlying cause of the disorder, rather than the symptoms

BIOMICA

* https://www.erandvieweaath.com/set/ssis/inflate/-syndoment-masket-state-Resert-nasket-state-Report%200veriew-4.4%23%20 0%20000

BMC321 & BMC322

Rationally designed consortia aimed to reduce inflammation for the treatment of IBD

· Orally administered capsule, comprised of 4 bacterial strains each, detected through Biomica's proprietary computational functional genomic analysis platform
· Strains were selected based on their anti-inflammatory functions targeting both immunocytes and intestinal mucosal cells
· The combination of 4 different microbial strains in a consortium is aimed to effectively attenuate inflammation through several complementary mechanisms
· Support growth and metabolism of other consortium members and the growth of additional favorable gut resident bacteria

Currently undergoing pre-clinical studies

BMC321 & BMC322 indicate to reduce inflammation in a DSS-treated mouse model*

Gut Inflammation level, During DSS treatment

*Preliminary results

Day 7 of DSS treatment 100 Severe 75 Mild-moderate % mice 50 25 0 STORE OF STORES

Inflammation status

Severe inflammation (% of total number of mice): Control - 43% VS. BMC322- 10%

3 C. difficile Infection (CDI) - Landscape

Gram-positive, anaerobic, spore-forming, toxinproducing bacillus

Most common hospital acquired infections (Over 600,000 a year)

Increasing cause of morbidity and mortality (older hospitalized patients) increasing in W.countries

Incidence & associated mortality progressively

15%-25% of all cases of antibiotic-associated diarrhea result from CDI

· Pathogenicity of C. difficile is mainly mediated by two exotoxins
· Infection manifestations:
· Diarrhea
· Abdominal cramping and pain
· Fever
· Nausea
· The economic cost of CDI est. as \$5.4Bn mostly due to hospitalization

Desai et al. BMC Infectious Diseases (2016) 16:303; Toxins 2016, 8, 134

BMC202

· Our approach is to utilize BMC202 as a non-antibiotic inhibitor of C. difficile toxin, which is responsible for the symptoms associated with CDI, while preserving healthy gut microbiome
BMC202 is a selective anti-bacterial agent designed to inhibit the glucosyl-transferase domain of the C. difficile toxin (TcdB)
· The drug candidate has been identified using Biomica's in silico chemical screening platform, which enables high throughput screening of a database of "300M molecules.

A collaboration between Biomica and the Weizmann Institute of Science

The company has in-licensed IP and knowhow generated by the Nobel Prize Laureate Prof. Ada Yonath, who supports Biomica's work on this program

Biomica develops a selective treatment against antibiotic resistant strains of Staphylococcus aureus (MRSA) infection, in a microbiome focused approach utilizing proprietary computational tools

· MRSA is a multi-drug resistant bacterium, responsible for several difficult-to-treat infections, leading to tens of thousands of annual cases of mortality in the US
· MRSA market in 2016 was approximately \$2.9Bn, projected to reach over \$3.9Bn by 2025 *.

w.prevswire.com/news-releases/gbbal-methicillin-resistant-staghylococus-aureus-market-to-reach-over-us-39-billion-by-2025-upsurge-in-the-consumption-ofbe-to-fuel-market-growth-observes-transparency-market-research-676949593.html

nature reviews drug discovery

NEWS · 11 SEPTEMBER 2020

First microbiome-based drug clears phase III, in clinical trial turnaround

Seres stoclamat Carrests

ton pusinesswire

and pusinesswire

19 SUSERS SECURITIES AND PERFECT FOR POST AND STORE OF PHOTOS OF THE
A CHISTORICAL POLICE SEMPER FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR FOR C

September 1930 % on microbiome trial successor
Creates stock

Seres Therapeutics' stool-derived treatment for recurrent Clostridium difficile infection could become the first FDA-approved microbiome therapy. Several other live biotherapeutic microbial products are close behind.

D	f	D

Ken Garber

and and and states and come and come mail and many comments of manimals of the mail of manimals of the mail and comments of the mail and comments of the mail.

The responsibl a Problem and Series Amounts Warlds Wards Maria, Marini, Andre

Svideo Strong America Amounts Warlds Warlds Provinsi, Androi
Norder Strump America Manufame Alassis Prefectio The recent positive Phase 3 clinical data provide strong validation for the utilization of microbiome therapeutics and helps validate Biomica's science and clinical approach, and demonstrates the potential value proposition of Biomica

BIOMICA -

Management

Dr. Elran Haber, CEO

· Previously served as the CEO of Therapix Biosciences (Nasdaq, TASE: TRPX), leading the company to a successful IPO on Nasdaq, and advancing the company's programs to clinical stage
· Spent more than 10 years as Chairman and board member of several privately held, and publicly traded, companies
· Served in senior executive roles in various life science companies and a private investment firm
· Holds a PhD in Pharmaceutical Science and an MBA in Finance & Financial Engineering, both from The Hebrew University of Jerusalem, Israel

Prof. Yehuda Ringel, CSO

· Chief Division of Gastroenterology and Hepatology at Meir Medical Center, Israel
· Professor of Medicine at Chapel Hill, North Carolina and is affiliated with University of North Carolina Hospitals
· Has more than 30 years of diverse experiences, especially in Gastroenterology and translational research, and an expert on IBS and functional motility disorders
· Recipient of several prestigious awards
· MD from Technion Institute of Technology, Israel

Dr. Shiri Meshner, VP of R&D

· Previously served as the head & principal investigator of the Dead Sea microbiology lab in the Dead Sea-Arava Science Center
· Spent over 5 years working in the pharma industry both in the US and in Israel (OSI pharmaceuticals and Teva pharmaceuticals)
· Holds a PhD in systems microbiology from the Department of Physics of Complex Systems at The Weizmann Institute

Board of Directors

Mr. Ofer Haviv, Chairman

· Serves as Evogene's (Nasdaq: EVGN), President and CEO as of late 2004. Prior to that he held the positions of Evogene's COO and CFO and was involved in the spin-off from Compugen
· Served as a Director of Finance and Treasurer at Compugen (NASDAQ: CGEN), includes two private placements and an IPO on NASDAQ

Mr. Doron Ben Ami, Director

· A seasoned executive with more than 20 years of management experience in the multinational biotech industry
· Served as Head of the Eastern Europe and Israel region at Merck (MSD), Managing Director of MSD Israel and previously as the General Manager of Lundbeck in Israel

Dr. Kinneret Savitsky, Director

· A seasoned Biopharma executive
· Serves as the CEO of FutuRx Ltd., the Israeli Biotechnology accelerator established by OrbiMed, Johnson & Johnson Innovation, JJDC and Takeda Pharmaceutical
· Currently serves as a Chairperson and Board member at number of privatly held healthcare/pharma companies
· Served as the CEO of BioLineRx Ltd. (Nasdaq: BLRX)

Prof. Yehuda Ringel, Director

Scientific Advisory Board & Advisors

Prof. Yehuda Ringel

Chief Division of Gastroenterology and Hepatology at Meir Medical Center, Israel. Professor of Medicine at Chapel Hill, North Carolina and is affiliated with University of North Carolina Hospitals.

Prof. Willem M De Vos

Professor and Chair of Microbiology at Wageningen University, the Netherlands and Professor of Human Microbiomics at the University of Helsinki, Finland.

Prof. R. Balfour Sartor

Serves as the Midget Distinguished Professor of Medicine, Microbiology and Immunology and Director of the Multidisciplinary IBD Center at the University of North Carolina, Chapel Hill.

Prof. James Versalovic

Pathologist-In-Chief at Texas Children's Hospital and Director of Texas Children's Microbiome Center, Professor and Vice Chair of Pathology & Immunology at Baylor College of Medicine.

Section chief of gastroenterology, hepatology, and nutrition at University of Chicago Medicine. Chair-elect of the National Scientific Advisory Committee of the Crohn's and Colitis Foundation.

Dr. Ravid Straussman

Principle investigator of the Tumor microenvironment, tumor microbiome and resistance to anti-cancer therapy lab at the Weizmann Institute of Science, Israel.

BIOMICA -

SUMMARY

· Human Microbiome based therapeutics is a rapidly growing space, represents a multi \$Bn market opportunity
· Biomica develops innovative microbiome-based therapeutics utilizing a dedicated computational predictive biology tools
· Biomica's computational tools have been specifically developed to allow the processing of large amounts of data to obtain high-resolution mapping of microbial profiles to deliver optimized drug candidates
· Focus on high-value clinical programs for the development of therapies for antibiotic resistant bacteria, Immuno-Oncology and microbiome-related gastrointestinal (GI) disorders.
· Experienced Management Team, Board of Directors and world class Scientific Advisory Board

13 Gad Feinstein St., Park Rehovot P.O.B 2100 Rehovot 76121, Israel

[email protected]

T. +9728 9311900/1 F. +972 8 9466724

Forward Looking Statement

This presentation cortains "forward-ooking to future events, and Canonic Ld (the "Company") and is parent, Evogene Ltd. ("Evogene") may from time to time make other statements, regardions for thurs financial or operaing results and/or other matters regarding or affecting us that are considered "forwarlooking statements" as defined in the U.S. Printer Securities and of 1995 (the "PSLA") and other securities hy be dentified by the use of such words as "believe", "exped", "should", "planned", "intend" and "potential" or words of similar meaning. We are using forward-boking statements in this presentation we disers, commercialization effors and timing, product development and launches, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predic and are of ture performane. There results, performance or achievenents, and trends in the future may differ materially from wat is expressed or mpled by such forward-looking statements of actors, nany of which are beyond our out linitation, those described in great detail in Evogene's Annual Report on Formation Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities aws we obligaton or commitment to update in this presentation or opublicy release the results of any revisions to any statements that may be nade or developments or changes in expectations, estimates, projections and assumptions.

The information contaned herein does not other offer offering document, nor does it constitute of form part of any soliciation of any initation or offer to purchase or subscribes of Evogene of the Company, nor shall the information or any part of it or the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the Company.

The tradenaris included heren are the owners thereof and are used for reference purposes only. Such use should not be construed of our products or services.

INTRODUCTION.

Company Overview

· Canonic was established in early 2019 as a spin-off from Evogene (NASDAQ, TASE: EVGN) focusing on medical cannabis
· Canonic has an exclusive license to develop cannabis varieties using Evogene's state-of-the-art computational genomics technology
· Distinct advantage to tackle market challenges by mapping, decoding and stabilizing the cannabis genetics
· Breeding infrastructure among the biggest in Israel and unique proprietary knowhow
· First generation varieties expected to produce premium quality products to connect the patients and market
· Product launch expected at early 2022- the company is evaluating its first-generation varieties with licensed growers and in preparation for commercial cultivation
· Company products expected to be launched under the "Canonic" brand in Israel followed by the EU and NA with local partners
· Next generation products expected to focus on 2 major medical indications, pain and inflammation that are >60% of the medical market*

*Company estimate, based on data published by Israeli Health Ministry regarding number of medical cannabis users in Israel

CANONIC

OUR VISION

Commercialize effective, precise and stable medical cannabis products, based on novel cannabis varieties, for optimized therapeutic impact

We are here because genetics can make cannabis much more effective

Watch Now >

Team

Directors and Advisory Board

Board of directors

Ofer Haviv Chairman of the board Evogene President & CEO

Business strategy Former CEO Koor industries

Dr. Yossi Tam Cannabinoid clinical research Director, Multidisciplinary Center for Cannabinoid Research of the Hebrew university

Advisors

Dr. Yariv Brotman Plant metabolic pathways Ben Gurion University & Max Planck institute of Molecular Plant Physiology

CANONIC

Dorit Kreiner Finance Evogene CFO

Shai Leviatov Plant breeding

Commercial varieties breeding for more than 30 years in top leading multinational seeds companies

Adv. Itay Rosenfeld Business strategy

Cannabis entrepreneur and former BOD member of Intelicanna (TLV: INTL)

Nirit Elyovich Marketing strategy

Senior marketing specialist with over 20 years of B2C experience in various markets

Global Cannabis Market

Medical cannabis is >60% of the global market

CANONIC -

Market Challenges & The Opportunity

THE CHALLENGES

STABILITY Substantial variations within varieties produce inconsistent products and therefore inconsistent results

YIELD More active compounds and income per sq foot

THE OPPORTUNITY - With state-of-the-art plant genomic expertise Canonic can solve major market challenges

CANONIC

From Plant Genetics - To Medical Cannabis Products

Plant genetic knowhow is the basis for development of premium Cannabis varieties

Premium varieties lead to novel medical Cannabis products addressing market challenges

CANONIC -

Proven Capabilities Along The Development Value Chain

The only company in Israel holding computational genomics capabilities and the full plant infrastructure to execute

- CANONIC -

The Genomic Power - Trait Improvement

- CANONIC -

When Genomics Meets Computational Biology

Computational Genomics

Combining deep scientific knowhow with Big Data and AI technology to tailor the plant genetic for improvement of plant traits and development of unique cannabis products

CANONIC -

Big Data & Al transforming Data to Knowhow

Canonic Holds Unique Knowhow in Plant Genetics

Controlling genetics > controlling plant traits > improving cannabis type & quality

Variety Families Under Development

MetaYield+

Stable enhancement of total plant compounds. Focus on agronomic and consumer traits.

Increased compounds per plant [e.g. Increased trichomes prevalence]

Increased compounds per area [e.g. Dwarf & early flowering]

First product launch expected in 2022

Precise+

Stable enhancement of specific active compounds Focus on therapeutic traits

Medical indication focus [e.g. Pain & Inflammation]

Compound profile focus [e.g. CBG, CBC]

First product launch expected in 2023

CANONIC

MetaYield+ : First Commercial Varieties

Canonic expects to commercialize its first varieties during 2022

Precise + : Next Generation Varieties

Collaboration With Tikun Olam-Cannbit as Part of Precise+ Product Development

Precise+

Stable enhancement of specific active compounds

Focus on therapeutic traits

Compound profile focus

CANONIC

Business model

Cannabis Value Chain

FROM GENOMICS TO PRODUCT

Canonic in the Cannabis Value Chain

Quickly and cost effectively reach the end user, by leveraging proprietary genomic expertise and outsourcing downstream elements of the value chain

Value Creation - Short Term Milestones

2021- pre commercial

· MetaYield -

* reach 1st commercial variety;
* sign production and distribution agreements in anticipation for commercialization in 2022
· Precise identify specific lines that exhibit distinct effect in model systems for reducing pain or inflammation

2022- commercial

· MetaYield commercial launch and initial sales of 1st product in Israel
· Precise reach 1st commercial variety for reducing pain or inflammation as preparation for commercial launch in 2023

CANONIC

Anticipated Commercial Milestones (5y)

CANONIC -

Cutting-Edge Technology Addressing Market Challenges

Summary

Canonic aims to develop novel varieties through a unique genomic approach and commercialize medical grade Cannabis	Product launch expected in 2022
Exclusive access to computational genomics technology	Infrastructure in place - from seed to sale
Commercial partners in place for cultivation, production and distribution (IL)	Leading academic partnerships for unique variety development

Exhibit 99.5

Forward looking statement

This presentation contains "forward-looking to future events, and Lavie Bio (the "Company") and its parent, Evogene Ltd. ("Evgene"), may from time to time make other statements, regardings for uture financial or operating results and or other matters regarding or affecting us hat are considered "forward-looking statements" as defines Litigation Reform Act of 1995 (the "PSLR4") and other securities laws. Such forward-hoking statements may be identified by the see "believe", "should", "planned", "should", "planned", "intend" and "potential" or words of similar meaning. We are using statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes as well as the capabilities of Evogene's and our technology,

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain risks and uncertaintes which are difficult to predict and are not guarance. Therefore, actual future results, performance or achievenents, and trends in the future may differ materially from what is expressed or impres-looking statements due to a variety of factors, many of which are beyond our control, including, without in those detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those for one in the heading "Risk Factors".

Except as required by applicable securities laws we obligation or commitment to update any information on this presentation or to publicy release the results of any statements that may be made to relect future events or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or offer to sell, or any solicitation of any invitation or offer to pursecurities of Evgene or the Company, nor shall the information or any part of the fact of its distribution form the basis of, or be relied on intract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

The fork influences the farm

Consumer preferences drive change and impact how food is grown

8 Healthier food Sustainable environment ્લ્વિ Productive agriculture Better 11. value

The Ag-Biologicals opportunity Driving healthier produce, sustainability and productive agriculture

The Ag-Biologicals untapped potential

	Crop Protection & Fertilizers	Ag-Biologicals Today
Sustainability	+	++++
Efficacy	++++	++
Consistency	++++	+
Commercial viability	++++	+
		6 · Company estimates

lavie bio

Improve food quality, sustainability and agriculture productivity through microbiome based ag-biologicals technology and products

The Ag-Biologicals Opportunity

	Crop Protection & Fertilizers	Ag-Biologicals Today	Next gen Ag-Biologicals
Sustainability	+	++++	++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Efficacy	++++	++	+++
Consistency	++++	+	1
Commercial viability	++++	+	++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ 8
			· Company estimates

lavie bio

The Microbiome:

Billions of microbes matter!

Biology Driven Design platform

The microbiome OS

Decoding the natural diversity & BDD of genetic functionality

Limitless possibilities, designs and functions: Go as far as imagination takes you

Nature's functional diversity

Proprietary Function Hub

Function based design

Path to market

Lavie Bio

Product Direct model

· Non consolidated segments
· Commercialization through channels
Revenues from sales .

Lavie Bio product & tech inside

Indirect model

· Consolidated segments
· Commercialization through partner's channels
· Revenues from R&D / Milestones and royalties

Lavie Bio tech inside

Indirect model

· Precision Optimization of 3rd party's products
· Short time to market
· Revenues from sales or R&D / Milestones and royalties

Product pipeline

Product Program	Product focus		Target market*	Potential expansion*	Pre- Commercialization	Product
Bio-Stimulants
LAV 211, 212 Bio-stimulants 1	Seed treatment, Spring Wheat North America	માં વિસ્ત	25M ACRES wheat North America	500M ACRES		2022
LAV 213, 218 Bio-stimulants 2	Seed treatment Corn North America Europe		120M ACRES corn US, EU	180M ACRES		>2025
Bio-Pesticides
LAV 311, 312 Fruit rots	Foliar F&V Europe North America	P	>\$200M grapes chemicals usage	+\$150M Additional F&V		2024
LAV 321, 322 Downey mildew	Foliar F&V Europe North America	C 196	> \$350M grapes chemicalsusage	+\$150M Additional F&V		2025
LAV 431, 432 Seedling disease (Pythium)	Seed Treatment, Corn, soy, F&V North America Europe		>\$500M	<\$200M		>2025
LAV 441, 442 Bio-Insecticides	Seed Treatment, Corn, foliar soy North America Europe		> \$1.5B existing traits and chemicals market	<\$500M		>2025
					· Company estimations	14